GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
Pre-Market: $43.47 -0.08 (-0.18%) 8:12 AM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
Pre-Market: $43.47 -0.08 (-0.18%) 8:12 AM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Halozyme (HALO) Inks Collaboration Deal With Glaxo's HIV Unit
by Zacks Equity Research
Halozyme (HALO) and Glaxo's HIV company, ViiV Healthcare sign a collaboration agreement, which gives the latter exclusive right to Halozyme's ENHANZE technology to develop therapies targeting HIV
The Zacks Analyst Blog Highlights: Exxon Mobil, Texas Instruments, GlaxoSmithKline, Norfolk Southern and Corning
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Exxon Mobil, Texas Instruments, GlaxoSmithKline, Norfolk Southern and Corning
Top Stock Reports for Exxon Mobil, Texas Instruments & GlaxoSmithKline
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil (XOM), Texas Instruments (TXN), and GlaxoSmithKline (GSK).
Theravance (TBPH) COVID-19 Therapy Fails in Mid-Stage Study
by Zacks Equity Research
Theravance's (TBPH) JAK inhibitor candidate, nezulcitinib, fails to achieve statistically significant improvement in the number of respiratory failure-free days in hospitalized COVID-19 patients with lung injury.
Glaxo (GSK)/Vir Affirm COVID-19 Drug Cuts Hospitalization/Death
by Zacks Equity Research
Glaxo (GSK)/Vir Biotech's new data confirms that COVID-19 treatment, sotrovimab can cut hospitalization and risk of death. ViiV Healthcare inks deal with Halozyme to use its ENHANZE technology to make better HIV medicines.
Gilead (GILD) Veklury Data Positive in Hospitalized COVID Patients
by Zacks Equity Research
Gilead (GILD) announces positive data on Veklury in hospitalized patients with COVID-19 across three analyses of large retrospective real-world data sets.
Pharma Stock Roundup: AZN COVID-19 Antibody Cocktail Failure, GSK New Cancer Deal
by Kinjel Shah
AstraZeneca's (AZN) phase III study on COVID-19 antibody cocktail fails to meet primary goal. Glaxo (GSK) signs a new co-development/commercialization deal for a cancer candidate with iTeos Therapeutics.
CureVac (CVAC) Plummets on Disappointing COVID-19 Vaccine Data
by Zacks Equity Research
CureVac (CVAC) down as it announces that its first-generation COVID-19 vaccine candidate, CVnCoV, did not meet the prespecified statistical success criteria in a phase IIb/III study.
Biotech Stock Roundup: SAGE Declines on Data, Regulatory Updates From VRTX, ITOS
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Sage (SAGE) and Vertex (VRTX), among others.
Regeneron (REGN) Announces Data on COVID-19 Antibody Cocktail
by Zacks Equity Research
Regeneron (REGN) announces positive results from a phase III study on antibody cocktail, REGEN-COV.
AstraZeneca (AZN) Antibody Cocktail Fails to Prevent COVID-19
by Zacks Equity Research
AstraZeneca's (AZN) antibody cocktail, AZD7442 fails to prevent people who were already infected from developing symptomatic COVID-19. However, it showed some efficacy in people who were not infected.
Glaxo (GSK)/iTeos Therapeutics to Co-Develop Novel Cancer Drug
by Zacks Equity Research
Glaxo (GSK) signs deal with iTeos Therapeutics to co-develop its investigational cancer candidate known as EOS-448. Glaxo will also study EOS-448 with its other investigational cancer therapies.
Gilead (GILD) Gets FDA Nod for Label Expansion of Epclusa
by Zacks Equity Research
Gilead (GILD) obtains FDA approval for the label expansion of HCV drug, Epclusa, to include children as well.
VBI Vaccines (VBIV) Up on Glioblastoma Drug Fast Track Status
by Zacks Equity Research
VBI Vaccines (VBIV) is developing VBI-1901 as a potential treatment of recurrent glioblastoma patients.
Sanofi (SNY) Stops Venglustat Development as Kidney Cyst Drug
by Zacks Equity Research
Sanofi (SNY) discontinues development of pipeline candidate, venglustat, in patients with autosomal dominant polycystic kidney disease, following failure in a pivotal study.
CureVac (CVAC) Announces Positive Data on COVID-19 Vaccine
by Zacks Equity Research
CureVac (CVAC) announces the continuation of its COVID-19 vaccine study following the first interim analysis in 59 eligible COVID-19 cases.
Pharma Stock Roundup: JNJ Cancer Drug Gets FDA Nod, PFE, GSK, SNY Begin New Studies
by Kinjel Shah
Sanofi (SNY) and Glaxo's (GSK) COVID-19 vaccine candidate enters phase III. FDA approves J&J's (JNJ) Rybrevant (amivantamab) for a rare lung cancer
Sanofi/Glaxo Initiate Pivotal Global COVID-19 Vaccine Study
by Zacks Equity Research
Sanofi (SNY) and Glaxo initiate phase III study to evaluate their adjuvanted COVID-19 vaccine candidate. A booster program will start soon.
Vir Biotech (VIR)/Glaxo COVID-19 Drug Gets FDA Emergency Nod
by Zacks Equity Research
Glaxo (GSK)/VIR Biotech's (VIR) sotrovimab demonstrated an 85% reduction in hospitalization or death in a study evaluating it in high-risk COVID-19 patients.
Merck (MRK) Gets CHMP Nod for Keytruda in Esophageal Cancer
by Zacks Equity Research
The CHMP recommends approval of Merck's (MRK) anti-PD-1 therapy, Keytruda in combination with chemotherapy for the first-line treatment of esophageal and gastroesophageal junction carcinoma in Europe.
Glaxo (GSK)/ Vir Biotech's COVID-19 Antibody Gets CHMP Nod
by Zacks Equity Research
The CHMP issues a positive scientific opinion on Glaxo (GSK) and partner Vir Biotech's antibody candidate, sotrovimab (VIR-7831), for the treatment of adults and adolescents with COVID-19 infection.
The Zacks Analyst Blog Highlights: Sanofi, GlaxoSmithKline, Pfizer, Eli Lilly and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sanofi, GlaxoSmithKline, Pfizer, Eli Lilly and Merck
Merck's (MRK) Pneumococcal Vaccine Succeeds in Pediatric Trials
by Zacks Equity Research
Merck's (MRK) 15-valent pneumococcal conjugate vaccine candidate, V114, demonstrates comparable immunogenicity and safety compared to a lower valency vaccine in infants and children.
Pharma Stock Roundup: GSK/SNY COVID-19 Vaccine Data, PFE's New EU Supply Deal
by Kinjel Shah
Sanofi (SNY) and Glaxo's (GSK) COVID-19 vaccine shows strong antibody response in phase II. Lilly's fifth phase III study on tirzepatide meets all key endpoints
The Zacks Analyst Blog Highlights: GlaxoSmithKline, Sanofi, CureVac and Vir Biotechnology
by Zacks Equity Research
The Zacks Analyst Blog Highlights: GlaxoSmithKline, Sanofi, CureVac and Vir Biotechnology